Published in Genes Dev on November 01, 2010
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev (2010) 1.61
YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle (2012) 1.34
Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation. EMBO J (2011) 1.26
p53: guardian of ploidy. Mol Oncol (2011) 1.25
ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ (2013) 1.05
The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ (2013) 1.04
LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction. Cell Rep (2013) 0.95
The p53 control of apoptosis and proliferation: lessons from Drosophila. Apoptosis (2014) 0.93
A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res (2012) 0.93
microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer (2014) 0.90
miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ (2013) 0.88
Regulation and function of the TAZ transcription co-activator. Int J Biochem Mol Biol (2011) 0.87
The Hippo pathway acts via p53 and microRNAs to control proliferation and proapoptotic gene expression during tissue growth. Biol Open (2013) 0.83
LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development. Nat Commun (2016) 0.83
RASSF Signalling and DNA Damage: Monitoring the Integrity of the Genome? Mol Biol Int (2012) 0.83
Lats2 is critical for the pluripotency and proper differentiation of stem cells. Cell Death Differ (2014) 0.82
Down-regulation of LATS kinases alters p53 to promote cell migration. Genes Dev (2015) 0.81
An indirect role for ASPP1 in limiting p53-dependent p21 expression and cellular senescence. EMBO J (2011) 0.79
The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes Dev (2016) 0.78
Hippo signaling: to die or not to die. Cell Death Differ (2013) 0.78
The interplay between centrosomes and the Hippo tumor suppressor pathway. Chromosome Res (2016) 0.76
Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways. Sci Rep (2016) 0.76
The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair. Genes (Basel) (2016) 0.75
LATS2 Positively Regulates Polycomb Repressive Complex 2. PLoS One (2016) 0.75
The Hippo pathway, p53 and cholesterol. Cell Cycle (2016) 0.75
Novel linkage disequilibrium clustering algorithm identifies new lupus genes on meta-analysis of GWAS datasets. Immunogenetics (2017) 0.75
Genetic ablation of the mammalian sterile-20 like kinase 1 (Mst1) improves cell reprogramming efficiency and increases induced pluripotent stem cell proliferation and survival. Stem Cell Res (2017) 0.75
An identity crisis for a cancer gene: subcellular location determines ASPP1 function. Cancer Cell (2010) 0.75
YAP tips the balance. Nat Rev Cancer (2010) 0.75
Contribution of LATS1 and LATS2 promoter methylation in OSCC development. J Cell Commun Signal (2016) 0.75
The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ (2017) 0.75
Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science (1996) 19.48
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell (2001) 4.38
Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 2.93
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res (2005) 2.67
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev (2009) 2.58
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev (2006) 2.41
The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell (2004) 2.16
Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J (2004) 2.12
ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer (2007) 1.94
The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ (2006) 1.72
BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ (2006) 1.72
Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res (2006) 1.67
Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res (2003) 1.64
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev (2010) 1.61
Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem (2001) 1.58
Restoration of p53 to limit tumor growth. Curr Opin Oncol (2008) 1.52
Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res (2006) 1.49
Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem (1999) 1.37
The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells (2004) 1.35
Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia (2005) 1.19
Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene (2009) 1.06
The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol (2004) 1.06
Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells (2009) 1.04
Downregulated mRNA expression of ASPP and the hypermethylation of the 5'-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett (2005) 1.04
Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res (2008) 1.03
Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. Genes Chromosomes Cancer (2005) 1.01
LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. Lung Cancer (2008) 1.01
ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene (2006) 1.00
Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood (2008) 0.92
Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem Biophys Res Commun (2009) 0.92
The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo. Oncogene (2006) 0.91
Up-regulation of GADD45alpha expression by NSAIDs leads to apoptotic and necrotic colon cancer cell deaths. Apoptosis (2009) 0.81
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Genome sequencing and analysis of the versatile cell factory Aspergillus niger CBS 513.88. Nat Biotechnol (2007) 6.21
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell (2009) 5.19
Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA (2012) 4.89
The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol (2003) 4.46
Improved response to disasters and outbreaks by tracking population movements with mobile phone network data: a post-earthquake geospatial study in Haiti. PLoS Med (2011) 4.38
Availability of consumer prices from US hospitals for a common surgical procedure. JAMA Intern Med (2013) 4.35
Global and local architecture of the mammalian microRNA-transcription factor regulatory network. PLoS Comput Biol (2007) 4.31
A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol Cell (2006) 3.98
The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab (2010) 3.61
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol (2008) 3.13
Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA (2011) 3.09
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat Cell Biol (2008) 3.08
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Living with p53, dying of p53. Cell (2007) 2.62
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene (2002) 2.50
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev (2008) 2.48
Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell (2008) 2.46
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet (2013) 2.44
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
Impact of telemedicine intensive care unit coverage on patient outcomes: a systematic review and meta-analysis. Arch Intern Med (2011) 2.41
A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev (2006) 2.41
Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med (2010) 2.32
The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell (2007) 2.32
Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29
Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res (2006) 2.29
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
The ecology, genetic diversity, and phylogeny of Huaiyangshan virus in China. J Virol (2011) 2.23
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer (2011) 2.18
The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell (2004) 2.16
Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. Mol Cell (2011) 2.16
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med (2009) 2.10
The p53 and Mdm2 families in cancer. Curr Opin Genet Dev (2002) 2.07
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol (2004) 2.04
Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 1.95
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
The association between hospital obstetrical volume and maternal postpartum complications. Am J Obstet Gynecol (2012) 1.90
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J (2005) 1.90
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci U S A (2010) 1.77
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Lats2 is an essential mitotic regulator required for the coordination of cell division. J Biol Chem (2007) 1.75
CKIα ablation highlights a critical role for p53 in invasiveness control. Nature (2011) 1.72
CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. EMBO Rep (2009) 1.69
The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis. Cell Cycle (2011) 1.69
ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell (2010) 1.68
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut (2010) 1.67
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64
Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res (2004) 1.59
Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res (2013) 1.58
Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem (2012) 1.58
Forceps delivery volumes in teaching and nonteaching hospitals: are volumes sufficient for physicians to acquire and maintain competence? Acad Med (2014) 1.55
Female ground tits prefer relatives as extra-pair partners: driven by kin-selection? Mol Ecol (2011) 1.54
Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. J Invest Dermatol (2007) 1.54
A boosting approach for motif modeling using ChIP-chip data. Bioinformatics (2005) 1.53
Lats2 is a negative regulator of myocyte size in the heart. Circ Res (2008) 1.53
RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation. Mol Cell (2012) 1.52
Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta (2009) 1.50
ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev (2006) 1.49
Insurance status and the transfer of hospitalized patients: an observational study. Ann Intern Med (2014) 1.49
p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res (2006) 1.48
Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation. Cell Cycle (2010) 1.47
Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis (2005) 1.46
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J (2002) 1.45
To die or not to die: how does p53 decide? Oncogene (2004) 1.45
p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. Mol Cell (2006) 1.44
A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst (2009) 1.43
Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal Chim Acta (2008) 1.43
Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest (2011) 1.42
Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. Clin Rheumatol (2014) 1.41
Adverse outcomes in hip arthroplasty: long-term trends. J Bone Joint Surg Am (2012) 1.40
RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. J Proteome Res (2008) 1.40
The impact of hospital cardiac specialization on outcomes after coronary artery bypass graft surgery: analysis of medicare claims data. Circ Cardiovasc Qual Outcomes (2010) 1.39
ASPP [corrected] and cancer. Nat Rev Cancer (2006) 1.38
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36